Amgen Announces FDA Approval of Kyprolis In Combination With Other Drugs

© Reuters.

By Sam Boughedda — Amgen Inc (NASDAQ:) announced Wednesday that the U.S. Food and Drug Administration has approved the use of its Kyprolis drug in combination with others to treat adult patients with relapsed or refractory multiple myeloma.

The FDA approved it in combination regime with Darzalex Faspro and dexamethasone.

Shares of the biotech firm are currently trading over 2.7% higher.

Amgen said the prescribing information expansion was supported by the ongoing, phase 2 trial. The study is evaluating the benefit of Darzalex Faspro given in combination with four standard-of-care treatment regimens.

“I am pleased that the addition of subcutaneous daratumumab to KYPROLIS plus dexamethasone will offer increased flexibility and convenience for patients with relapsed or refractory multiple myeloma and will greatly reduce the administration burden,” stated David M. Reese, executive vice president of Research and Development at Amgen. 

According to the company, serious adverse reactions occurred in 27% of patients who received Kyprolis combined with Darzalex Faspro and dexamethasone.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.